Efficacy and safety of canakinumab in patients with Adult-Onset Still’s Disease: Results from an open-label Phase III study in Japan

Although the primary endpoint was not met, week 28 analysis showed that canakinumab treatment led to improvements in various efficacy outcome measures in Japanese patients with AOSD, with no unexpected safety signals.